domingo, 4 de octubre de 2026
BuscarExplore
es.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· January 15, 2026

Sunset Pier 94 Studios Announces Inaugural Lease with Paramount Television Studios for Dexter®: Resurrection Ahead of Opening

View original at finance.yahoo.com
Sunset Pier 94 Studios Announces Inaugural Lease with Paramount Television Studios for Dexter®: Resurrection Ahead of Opening Paramount Television Studios Has Leased 70,000 Square Feet for Filming Season Two of the Hit Showtime® Original Series NEW YORK, January 15, 2026--(BUSINESS WIRE)--Today, Vornado Realty Trust (N…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Paramount Television Studios is thrilled to bring the second season of Dexter: Resurrection to Sunset Pier 94 Studios and its state-of-the-art facilities and sound stages

    80% confidence

  • Sunset Pier 94 Studios is expected to create 400 permanent jobs and contribute $6.4 billion to the local economy over the next 30 years

    80% confidence

  • Sunset Studios' success in attracting and retaining top-tier productions across multiple seasons speaks to the caliber of studios and services

    80% confidence

  • Last season saw Dexter move to New York City and now the production will follow suit, gaining greater access to the region's incredible creative talent

    80% confidence

  • Robust pre-leasing interest in Sunset Pier 94 Studios underscores the project's unmatched quality and prime location with nothing else like it in the market

    80% confidence

  • Season one of Dexter: Resurrection was filmed in New York, generating significant economic impact in neighborhoods through jobs and small business spending

    80% confidence

Citado en estos reportajes de Via News

Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,985
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,985 hechos verificados con la fuente5,340 documentos fuente archivados
Consulta estos datos → isubstrate.com